The US Food and Drug Administration (FDA) passed the daclizumab (Zinbryta, Biogen Idec) today for treatment of sufferers with relapsing forms of multiple sclerosis (MS), in accordance to an FDA news release.
The agency cautions, although, that the drug should be used only in sufferers who have failed to respond to one or two prior therapies, as the new agent has serious safety risks, including potentially severe liver damage and immune conditions.
The drug is offererd by self-administered subcutaneous injection once a month.
"Zinbryta provides an additional choice to patients who may require a new option for treatment," said William Dunn, MD, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, in the release.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment